350258 <common-name>2-[[5-(4-bromophenyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]-n-[(e)-(4-phenylmethoxyphenyl)methylideneamino]acetamide</common-name> <description>2-[[5-(4-bromophenyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]-n-[(e)-(4-phenylmethoxyphenyl)methylideneamino]acetamide is a chemical compound with the formula C30H24BrN5O2S. With an average molecular weight of 598.50 g/mol, 2-[[5-(4-bromophenyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]-n-[(e)-(4-phenylmethoxyphenyl)methylideneamino]acetamide is a heavy molecule.</description> <cas>303092-84-4</cas> <pubchem-id>6891816</pubchem-id> <chemical-formula>C30H24BrN5O2S</chemical-formula> <weight>598.5</weight> <appearance nil="true"/> <melting-point nil="true"/> <boiling-point nil="true"/> <density nil="true"/> <solubility nil="true"/> <specific-gravity nil="true"/> <flash-point nil="true"/> <vapour-pressure nil="true"/> <route-of-exposure nil="true"/> <target nil="true"/> <mechanism-of-toxicity nil="true"/> <metabolism nil="true"/> <toxicity nil="true"/> <lethaldose nil="true"/> <carcinogenicity nil="true"/> <use-source nil="true"/> <min-risk-level nil="true"/> <health-effects nil="true"/> <symptoms nil="true"/> <treatment nil="true"/> <created-at type="dateTime">2026-08-31T15:13:11Z</created-at> <updated-at type="dateTime">2026-08-31T15:13:11Z</updated-at> <interacting-proteins nil="true"/> <wikipedia nil="true"/> <uniprot-id nil="true"/> <kegg-compound-id nil="true"/> <omim-id nil="true"/> <chebi-id nil="true"/> <biocyc-id nil="true"/> <ctd-id nil="true"/> <stitch-id nil="true"/> <drugbank-id nil="true"/> <pdb-id nil="true"/> <actor-id nil="true"/> <organism nil="true"/> <export type="boolean">true</export> <metabolizing-proteins nil="true"/> <transporting-proteins nil="true"/> <moldb-smiles>C1=CC=C(C=C1)COC2=CC=C(C=C2)C=NNC(=O)CSC3=NN=C(N3C4=CC=CC=C4)C5=CC=C(C=C5)Br</moldb-smiles> <moldb-formula>C30H24BrN5O2S</moldb-formula> <moldb-inchi>InChI=1S/C30H24BrN5O2S/c31-25-15-13-24(14-16-25)29-34-35-30(36(29)26-9-5-2-6-10-26)39-21-28(37)33-32-19-22-11-17-27(18-12-22)38-20-23-7-3-1-4-8-23/h1-19H,20-21H2,(H,33,37)/b32-19+</moldb-inchi> <moldb-inchikey>KCJUZBTXKFFJKF-BIZUNTBRSA-N</moldb-inchikey> <moldb-average-mass type="decimal" nil="true"/> <moldb-mono-mass type="decimal">597.08341</moldb-mono-mass> <origin nil="true"/> <state nil="true"/> <logp>6.7</logp> <hmdb-id nil="true"/> <chembl-id nil="true"/> <chemspider-id nil="true"/> <structure-image-file-name nil="true"/> <structure-image-content-type nil="true"/> <structure-image-file-size type="integer" nil="true"/> <structure-image-updated-at type="dateTime" nil="true"/> <biodb-id nil="true"/> <synthesis-reference nil="true"/> <structure-image-caption nil="true"/> <chemdb-id>CHEM346151</chemdb-id> <dsstox-id nil="true"/> <toxcast-id nil="true"/> <stoff-ident-origin nil="true"/> <stoff-ident-id nil="true"/> <susdat-id nil="true"/> <iupac>2-[[5-(4-bromophenyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]-n-[(e)-(4-phenylmethoxyphenyl)methylideneamino]acetamide</iupac> <moldb-polar-surface-area nil="true"/> <moldb-refractivity nil="true"/> <moldb-polarizability nil="true"/> <moldb-rotatable-bond-count nil="true"/> <moldb-acceptor-count nil="true"/> <moldb-donor-count nil="true"/> <moldb-pka-strongest-acidic nil="true"/> <moldb-pka-strongest-basic nil="true"/> <moldb-physiological-charge nil="true"/> <moldb-number-of-rings nil="true"/> <moldb-alogps-logp nil="true"/> <moldb-alogps-logs nil="true"/> <moldb-alogps-solubility nil="true"/> <kingdom>Organic compounds</kingdom> <superklass>Organoheterocyclic compounds</superklass> <klass>Azoles</klass> <subklass>Triazoles</subklass> <paper-count type="integer" nil="true"/> <sync-id>CED0300565</sync-id> <structure-inchikey>KCJUZBTXKFFJKF-UHFFFAOYSA-N</structure-inchikey> <structure-fingerprint>40004000200000800002100800000000000000000000000000000000000002000000000402200004008000002084000000000000000000000000200000000000000000000000000000000000000022000000000300000204800050000000000000010000000000000080000000800400080100000000000000000000000000004000200000800000000000000084880000010100000000000000000000000000000000000000000000080000000000000000480000000000002c00000000000000004000000000000100004000000000000000002000000220000000000000000040000000001048000000000400000000010000000040000000004020</structure-fingerprint> <structure-pattern-fingerprint>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</structure-pattern-fingerprint> <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAAnAAAAKwAAAIABBkBoAAAAAwMBBkBoAAAA AwMBBkBoAAAAAwMBBkAoAAAAAwQGQGgAAAADAwEGQGgAAAADAwEGAGAAAAAC AggAKAAAAAMCBkAoAAAAAwQGQGgAAAADAwEGQGgAAAADAwEGQCgAAAADBAZA aAAAAAMDAQZAaAAAAAMDAQYAaAAAAAMDAQcAKAAAAAMDBwBoAAAAAwIBBgAo AAAAAwQIACgAAAADAgYAYAAAAAICEAAgAAAAAgZAKAAAAAMEB0AoAAAAAwMH QCgAAAADAwZAKAAAAAMEB0AoAAAAAwMGQCgAAAADBAZAaAAAAAMDAQZAaAAA AAMDAQZAaAAAAAMDAQZAaAAAAAMDAQZAaAAAAAMDAQZAKAAAAAMEBkBoAAAA AwMBBkBoAAAAAwMBBkAoAAAAAwQGQGgAAAADAwEGQGgAAAADAwEjACAAAAAB CwABaAwBAmgMAgNoDAMEaAwEBWgMAwYABgcABwggCAloDAkKaAwKC2gMCwxo DAwNaAwLDiAODygCDxAgEBEgERIoAhETABMUABQVABUWaAwWF2gMFxhoDBgZ aAwZGiAaG2gMGxxoDBwdaAwdHmgMHh9oDBggICAhaAwhImgMIiNoDCMkaAwk JWgMIyYABQBoDA0IaAwZFWgMHxpoDCUgaAxCBQAAAAYABQQDAgEGCQoLDA0I BRYVGRgXBhscHR4fGgYhIiMkJSAXBAAAAAAAAAAW </structure-pickle> <structure-indexed-at type="dateTime">2026-09-19T05:48:14Z</structure-indexed-at> </compound>